← Eichor
Condition: Progressive Pulmonary Fibrosis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Progressive Pulmonary Fibrosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Phase 2 · 54 location(s) · Avalyn Pharma Inc. · NCT06951217Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
NA · 1 location(s) · Oslo University Hospital · NCT06732674A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Pro
Phase 2 · 1 location(s) · Sunshine Lake Pharma Co., Ltd. · NCT05139719P4O2 ILD Extension
Phase N/A · 1 location(s) · Amsterdam UMC, location VUmc · NCT06644144A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis
Phase N/A · 1 location(s) · Qianfoshan Hospital · NCT05895409Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis
Phase N/A · 1 location(s) · University of California, Los Angeles · NCT06162884A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Pr
Phase 3 · 373 location(s) · Boehringer Ingelheim · NCT06238622PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
Phase N/A · 13 location(s) · University of Massachusetts, Worcester · NCT06855329Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial
NA · 1 location(s) · Hospital de Granollers · NCT07486206A Prospective, Multi-Center Registry Study of Progressive Pulmonary Fibrosis (PPF) in China (PROFINA)
Phase N/A · 1 location(s) · Zuojun Xu · NCT07683728SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
NA · 1 location(s) · Medical University of South Carolina · NCT07269262Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Phase 3 · 165 location(s) · United Therapeutics · NCT05943535A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Ant
Phase N/A · 1 location(s) · Royal Brompton & Harefield NHS Foundation Trust · NCT07332117Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis
Phase 2 · 1 location(s) · Peter Caravan · NCT07572383Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis
NA · 1 location(s) · China-Japan Friendship Hospital · NCT06251687Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Phase N/A · 44 location(s) · Duke University · NCT01915511Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
Phase 2 · 5 location(s) · Vejle Hospital · NCT06714123Advanced Mutidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progres
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06537934Finger Versus Earlobe Pulse Oximetry During the 6-Minute Walk Test in Interstitial Lung Disease
Phase N/A · 1 location(s) · Hospital de Granollers · NCT07723872Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.
NA · 1 location(s) · Katerina M. Antoniou · NCT07466420Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07541638
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.